2008 ACPE
Self Study
ACPE Standards
Appendices
Supporting Documents
Prospective Students
Application Deadline March 2, 2010
Admissions
Pre-Requisites
Professional Pharmacy Curriculum
Laptop Information
Academic Programs
Bachelor of Science - Toxicology
Doctor of Pharmacy - Pharm.D.
Master of Science
Doctor of Philosophy - Ph.D.
Academic Departments
Basic Pharmaceutical Sciences
Clinical & Administrative Sciences
Toxicology
Graduate Studies and Research
Service Departments
Outcomes, Research & Evaluation
Experiential Education
Student & Professional Affairs
Mission, Planning and Assessment
Drug Information Center
Alumni Affairs
Technology Support
Administration
Organizational Chart
Business Office
Floor Plans
Policy and Procedures
Forms
Committees
Faculty
Directory
Calendar
Library Resources
Resources
Vivarium
Current Students
Exam Schedule
Organizations
Class Photos
Career Development Plan
Links
Syllabi
Reference Resources
Policy and Procedures
Alumni and Friends
Le Pharmacien Louisianais
Giving
Events
Update Alumni Info
Toxicology Alumni
COP Online Store
Assistant Professor of Pharmacology
Bienville 370
Department of Basic Pharmaceutical Sciences
College of Pharmacy
University of Louisiana at Monroe
Monroe, LA 71209-0497
email: kjackson@ulm.edu
ph: 318-342-1390
fax: 318-342-1737
| Curriculum Vitae | Scientific Society Offices | Publications | Lab | Teaching | Honors/Awards |
Research Interests
Hypertension is known as the “silent killer” in that it affects more than 65 million Americans, but over 20 million of them don't know it. Hypertension goes unnoticed in its early onset, because affected individuals initially feel no adverse symptoms. Unfortunately even though hypertensive individuals don’t have outward signs and symptoms, serious medical consequences are occurring during this silent phase of hypertension.
Currently our laboratory is studying the role of carbon monoxide in angiotensin II dependent hypertension. Angiotensin II is a hormone produced in the body that promotes potent vascular vasoconstriction and salt and water retention. Angiotensin II levels have been reported to be abnormally elevated in several forms of hypertension. Current literature supports a role for angiotensin II leading to the deleterious end-organ damage and medical crisis seen in hypertensive patients.
Carbon monoxide is an endogenous gas produced in the body and has been demonstrated to produce smooth muscle dependent vasodilation and endothelial dependent vasoconstriction. Angiotensin II has been shown to upregulate carbon monoxide production, yet the role of carbon monoxide in angiotensin II dependent hypertension has yet to be elucidated. Thus, our laboratory is zealously studying carbon monoxide and its potential as a novel treatment strategy to help eradicate the hypertensive disorder.